Understanding Why Regeneron Pharmaceuticals' Stock Has Gained 25% In 2 Months

Regeneron Pharmaceuticals (REGN) is a U.S.-based biotech company focused on manufacturing novel biologics. The company’s recent share price rally was facilitated by strong 3rd quarter results, with sales increasing 23% and net income improving 13% year-on-year. A key factor behind these strong results was an increase in Dupixent sales by 141%. This drug was launched in partnership with Sanofi, and was recently approved to treat eczema in children in Europe – something that is expected to add to company’s sales and profitability going forward.

We step back from these recent swings to review Regeneron Pharmaceuticals performance over the last few years, as a context for what might come next. Our Interactive dashboard – Why has Regeneron Pharmaceuticals’ stock rallied by 25% over last 2 months?, reviews the near term reasons and the big picture.


The context for the last few years:

A closer look At Regeneron Pharmaceuticals Total Revenues over the last few years and the outlook

Revenues for Regeneron Pharmaceuticals increased from $5.87 Bil in 2017 to $6.71 Bil in 2018 – a 14.3% increase.

This compares with Revenues growth of:

  • 18.4% in 2016
  • 20.8% in 2017

We expect Revenues growth to be 15.9% in 2019.


A closer look At Regeneron Pharmaceuticals Total Expenses over the last few years and the outlook

Total Expense for Regeneron Pharmaceuticals increased from $3.8 Bil in 2017 to $4.2 Bil in 2018 – an increase of 10.1%.

This compares with Total Expense growth of:

  • 23.4% in 2016
  • 7.9% in 2017

We expect Total Expense to grow by 7.5% in 2019.


How does Regeneron Pharmaceuticals Revenue Growth compare with rivals?

For more information on how Regeneron Pharmaceuticals’ revenue growth compares with Biogen, Celgene Corporation and Alexion Pharmaceuticals, view our interactive dashboard analysis.


How has  Regeneron Pharmaceuticals  EBT trended?

Earnings Before Taxes (EBT) for Regeneron Pharmaceuticals increased from $2.1 Bil in 2017 to $2.55 Bil in 2018 – an increase of 22.9%.

This compares with EBT growth of:

  • 8.5% in 2016
  • 56.3% in 2017

We expect EBT growth to be 27.6% in 2019.


How has Regeneron Pharmaceuticals Net Income and EPS trended?

For more details about Regeneron Pharmaceuticals’ Net Income and EPS, view our interactive dashboard analysis


What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

More Trefis Data

Like our charts? Explore example interactive dashboards and create your own.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics

US Markets Investing

Latest Stocks Videos


    Trefis is an interactive financial community structured around trends, forecasts and insights related to some of the most popular stocks in the US. Whereas most finance sites simply give you the facts about where a stock has been and what a company has done in the past, Trefis focuses entirely on the future.

    Learn More